APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Drug Conjugate

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Peptide Drug Conjugate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025199 pages

Choose your research edition.

Industry ResearchPeptide Drug Conjugate Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Drug Conjugate Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Peptide Drug Conjugate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Drug Conjugate Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Drug Conjugate Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Peptide Drug Conjugate market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Peptide Drug Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide Drug Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide Drug Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Peptide Drug Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Peptide Drug Conjugate include Zhongshan Laibo Ruichen Biopharmaceutical, XINOGEN (HONG KONG) PHARMA, Tianjin Conjustar Biotechnology, Lumosa Therapeutics, Shanghai Pharmaceuticals, Shanghai Huiyong Pharmaceutical, Gaorui Yaoye(Beijing)Technologies, BrightGene Bio-Medical Technology and Beijing Shenogen Pharma Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peptide Drug Conjugate market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide Drug Conjugate and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide Drug Conjugate sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide Drug Conjugate market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide Drug Conjugate Segment by Company

Zhongshan Laibo Ruichen Biopharmaceutical

XINOGEN (HONG KONG) PHARMA

Tianjin Conjustar Biotechnology

Lumosa Therapeutics

Shanghai Pharmaceuticals

Shanghai Huiyong Pharmaceutical

Gaorui Yaoye(Beijing)Technologies

BrightGene Bio-Medical Technology

Beijing Shenogen Pharma Group

Theratechnologies

Cybrexa Therapeutics

Bicycle Therapeutics

Peptide Drug Conjugate Segment by Type

Cell Targeting Peptides (CTP)

Cell-penetrating Peptides (CPP)

Others

Peptide Drug Conjugate Segment by Application

Breast Cancer

Pancreatic Cancer

Others

Peptide Drug Conjugate Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Drug Conjugate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Drug Conjugate and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Drug Conjugate.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide Drug Conjugate market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Peptide Drug Conjugate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Peptide Drug Conjugate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Peptide Drug Conjugate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Peptide Drug Conjugate Industry Trends Table 2. Peptide Drug Conjugate Industry Drivers Table 3. Peptide Drug Conjugate Industry Opportunities and Challenges Table 4. Peptide Drug Conjugate Industry Restraints Table 5. Global Peptide Drug Conjugate Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Peptide Drug Conjugate Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Peptide Drug Conjugate Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Peptide Drug Conjugate Sales Market Share by Manufacturers Table 9. Global Peptide Drug Conjugate Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global Peptide Drug Conjugate Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Peptide Drug Conjugate Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Peptide Drug Conjugate Manufacturers, Product Type & Application Table 13. Global Peptide Drug Conjugate Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Peptide Drug Conjugate by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Cell Targeting Peptides (CTP) Table 17. Major Manufacturers of Cell-penetrating Peptides (CPP) Table 18. Major Manufacturers of Others Table 19. Global Peptide Drug Conjugate Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Peptide Drug Conjugate Sales by Type (2021-2026) & (k units) Table 21. Global Peptide Drug Conjugate Sales by Type (2027-2032) & (k units) Table 22. Global Peptide Drug Conjugate Sales Market Share by Type (2021-2026) Table 23. Global Peptide Drug Conjugate Sales Market Share by Type (2027-2032) Table 24. Global Peptide Drug Conjugate Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Peptide Drug Conjugate Revenue by Type (2021-2026) & (k units) Table 26. Global Peptide Drug Conjugate Revenue by Type (2027-2032) & (k units) Table 27. Global Peptide Drug Conjugate Revenue Market Share by Type (2021-2026) Table 28. Global Peptide Drug Conjugate Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Breast Cancer Table 30. Major Manufacturers of Pancreatic Cancer Table 31. Major Manufacturers of Others Table 32. Global Peptide Drug Conjugate Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Peptide Drug Conjugate Sales by Application (2021-2026) & (k units) Table 34. Global Peptide Drug Conjugate Sales by Application (2027-2032) & (k units) Table 35. Global Peptide Drug Conjugate Sales Market Share by Application (2021-2026) Table 36. Global Peptide Drug Conjugate Sales Market Share by Application (2027-2032) Table 37. Global Peptide Drug Conjugate Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Peptide Drug Conjugate Revenue by Application (2021-2026) & (k units) Table 39. Global Peptide Drug Conjugate Revenue by Application (2027-2032) & (k units) Table 40. Global Peptide Drug Conjugate Revenue Market Share by Application (2021-2026) Table 41. Global Peptide Drug Conjugate Revenue Market Share by Application (2027-2032) Table 42. Global Peptide Drug Conjugate Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Peptide Drug Conjugate Sales by Region (2021-2026) & (k units) Table 44. Global Peptide Drug Conjugate Sales Market Share by Region (2021-2026) Table 45. Global Peptide Drug Conjugate Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Peptide Drug Conjugate Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Peptide Drug Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Peptide Drug Conjugate Sales by Country (2021-2026) & (k units) Table 49. North America Peptide Drug Conjugate Sales by Country (2027-2032) & (k units) Table 50. Europe Peptide Drug Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Peptide Drug Conjugate Sales by Country (2021-2026) & (k units) Table 52. Europe Peptide Drug Conjugate Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Peptide Drug Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Peptide Drug Conjugate Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Peptide Drug Conjugate Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Peptide Drug Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Peptide Drug Conjugate Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Peptide Drug Conjugate Sales by Country (2027-2032) & (k units) Table 59. Global Peptide Drug Conjugate Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Peptide Drug Conjugate Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Peptide Drug Conjugate Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Peptide Drug Conjugate Revenue Market Share by Region (2021-2026) Table 63. Global Peptide Drug Conjugate Revenue Market Share by Region (2027-2032) Table 64. Zhongshan Laibo Ruichen Biopharmaceutical Company Information Table 65. Zhongshan Laibo Ruichen Biopharmaceutical Business Overview Table 66. Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Product Portfolio Table 68. Zhongshan Laibo Ruichen Biopharmaceutical Recent Development Table 69. XINOGEN (HONG KONG) PHARMA Company Information Table 70. XINOGEN (HONG KONG) PHARMA Business Overview Table 71. XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Product Portfolio Table 73. XINOGEN (HONG KONG) PHARMA Recent Development Table 74. Tianjin Conjustar Biotechnology Company Information Table 75. Tianjin Conjustar Biotechnology Business Overview Table 76. Tianjin Conjustar Biotechnology Peptide Drug Conjugate Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Tianjin Conjustar Biotechnology Peptide Drug Conjugate Product Portfolio Table 78. Tianjin Conjustar Biotechnology Recent Development Table 79. Lumosa Therapeutics Company Information Table 80. Lumosa Therapeutics Business Overview Table 81. Lumosa Therapeutics Peptide Drug Conjugate Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Lumosa Therapeutics Peptide Drug Conjugate Product Portfolio Table 83. Lumosa Therapeutics Recent Development Table 84. Shanghai Pharmaceuticals Company Information Table 85. Shanghai Pharmaceuticals Business Overview Table 86. Shanghai Pharmaceuticals Peptide Drug Conjugate Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Shanghai Pharmaceuticals Peptide Drug Conjugate Product Portfolio Table 88. Shanghai Pharmaceuticals Recent Development Table 89. Shanghai Huiyong Pharmaceutical Company Information Table 90. Shanghai Huiyong Pharmaceutical Business Overview Table 91. Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Product Portfolio Table 93. Shanghai Huiyong Pharmaceutical Recent Development Table 94. Gaorui Yaoye(Beijing)Technologies Company Information Table 95. Gaorui Yaoye(Beijing)Technologies Business Overview Table 96. Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Product Portfolio Table 98. Gaorui Yaoye(Beijing)Technologies Recent Development Table 99. BrightGene Bio-Medical Technology Company Information Table 100. BrightGene Bio-Medical Technology Business Overview Table 101. BrightGene Bio-Medical Technology Peptide Drug Conjugate Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. BrightGene Bio-Medical Technology Peptide Drug Conjugate Product Portfolio Table 103. BrightGene Bio-Medical Technology Recent Development Table 104. Beijing Shenogen Pharma Group Company Information Table 105. Beijing Shenogen Pharma Group Business Overview Table 106. Beijing Shenogen Pharma Group Peptide Drug Conjugate Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Beijing Shenogen Pharma Group Peptide Drug Conjugate Product Portfolio Table 108. Beijing Shenogen Pharma Group Recent Development Table 109. Theratechnologies Company Information Table 110. Theratechnologies Business Overview Table 111. Theratechnologies Peptide Drug Conjugate Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Theratechnologies Peptide Drug Conjugate Product Portfolio Table 113. Theratechnologies Recent Development Table 114. Cybrexa Therapeutics Company Information Table 115. Cybrexa Therapeutics Business Overview Table 116. Cybrexa Therapeutics Peptide Drug Conjugate Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Cybrexa Therapeutics Peptide Drug Conjugate Product Portfolio Table 118. Cybrexa Therapeutics Recent Development Table 119. Bicycle Therapeutics Company Information Table 120. Bicycle Therapeutics Business Overview Table 121. Bicycle Therapeutics Peptide Drug Conjugate Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Bicycle Therapeutics Peptide Drug Conjugate Product Portfolio Table 123. Bicycle Therapeutics Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. Peptide Drug Conjugate Distributors List Table 127. Peptide Drug Conjugate Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Peptide Drug Conjugate Product Image Figure 2. Global Peptide Drug Conjugate Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Drug Conjugate Market Size (2021-2032) & (US$ Million) Figure 4. Global Peptide Drug Conjugate Sales (2021-2032) & (k units) Figure 5. Global Peptide Drug Conjugate Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Peptide Drug Conjugate Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Cell Targeting Peptides (CTP) Image Figure 9. Cell-penetrating Peptides (CPP) Image Figure 10. Others Image Figure 11. Global Peptide Drug Conjugate Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Peptide Drug Conjugate Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Peptide Drug Conjugate Sales Market Share by Type (2021-2032) Figure 14. Global Peptide Drug Conjugate Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Peptide Drug Conjugate Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Peptide Drug Conjugate Revenue Market Share by Type (2021-2032) Figure 17. Breast Cancer Image Figure 18. Pancreatic Cancer Image Figure 19. Others Image Figure 20. Global Peptide Drug Conjugate Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Peptide Drug Conjugate Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Peptide Drug Conjugate Sales Market Share by Application (2021-2032) Figure 23. Global Peptide Drug Conjugate Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Peptide Drug Conjugate Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Peptide Drug Conjugate Revenue Market Share by Application (2021-2032) Figure 26. North America Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Peptide Drug Conjugate Sales Market Share by Country (2021-2032) Figure 28. U.S. Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Peptide Drug Conjugate Sales Market Share by Country (2021-2032) Figure 33. Germany Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Peptide Drug Conjugate Sales Market Share by Country (2021-2032) Figure 40. China Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Peptide Drug Conjugate Sales Market Share by Country (2021-2032) Figure 48. Brazil Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Peptide Drug Conjugate Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Peptide Drug Conjugate Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Peptide Drug Conjugate Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Figure 59. North America Peptide Drug Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Figure 61. Europe Peptide Drug Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Peptide Drug Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Peptide Drug Conjugate Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Peptide Drug Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Peptide Drug Conjugate Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Peptide Drug Conjugate Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Cell Targeting Peptides (CTP)
  • Cell-penetrating Peptides (CPP)
  • Others
Applications
  • Breast Cancer
  • Pancreatic Cancer
  • Others
Companies covered
  • Zhongshan Laibo Ruichen Biopharmaceutical
  • XINOGEN (HONG KONG) PHARMA
  • Tianjin Conjustar Biotechnology
  • Lumosa Therapeutics
  • Shanghai Pharmaceuticals
  • Shanghai Huiyong Pharmaceutical
  • Gaorui Yaoye(Beijing)Technologies
  • BrightGene Bio-Medical Technology
  • Beijing Shenogen Pharma Group
  • Theratechnologies
  • Cybrexa Therapeutics
  • Bicycle Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Peptide Drug Conjugate Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Peptide Drug Conjugate Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Peptide Drug Conjugate Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Peptide Drug Conjugate Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Peptide Drug Conjugate Market Dynamics
  1. 2.1 Peptide Drug Conjugate Industry Trends
  2. 2.2 Peptide Drug Conjugate Industry Drivers
  3. 2.3 Peptide Drug Conjugate Industry Opportunities and Challenges
  4. 2.4 Peptide Drug Conjugate Industry Restraints
3 Peptide Drug Conjugate Market by Manufacturers
  1. 3.1 Global Peptide Drug Conjugate Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Peptide Drug Conjugate Sales by Manufacturers (2021-2026)
  3. 3.3 Global Peptide Drug Conjugate Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Peptide Drug Conjugate Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Peptide Drug Conjugate Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Peptide Drug Conjugate Manufacturers, Product Type & Application
  7. 3.7 Global Peptide Drug Conjugate Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Peptide Drug Conjugate Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Peptide Drug Conjugate Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Peptide Drug Conjugate Tier 1, Tier 2, and Tier 3
4 Peptide Drug Conjugate Market by Type
  1. 4.1 Peptide Drug Conjugate Type Introduction
  2. 4.1.1 Cell Targeting Peptides (CTP)
  3. 4.1.2 Cell-penetrating Peptides (CPP)
  4. 4.1.3 Others
  5. 4.2 Global Peptide Drug Conjugate Sales by Type
  6. 4.2.1 Global Peptide Drug Conjugate Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Peptide Drug Conjugate Sales by Type (2021-2032)
  8. 4.2.3 Global Peptide Drug Conjugate Sales Market Share by Type (2021-2032)
  9. 4.3 Global Peptide Drug Conjugate Revenue by Type
  10. 4.3.1 Global Peptide Drug Conjugate Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Peptide Drug Conjugate Revenue by Type (2021-2032)
  12. 4.3.3 Global Peptide Drug Conjugate Revenue Market Share by Type (2021-2032)
5 Peptide Drug Conjugate Market by Application
  1. 5.1 Peptide Drug Conjugate Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Pancreatic Cancer
  4. 5.1.3 Others
  5. 5.2 Global Peptide Drug Conjugate Sales by Application
  6. 5.2.1 Global Peptide Drug Conjugate Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide Drug Conjugate Sales by Application (2021-2032)
  8. 5.2.3 Global Peptide Drug Conjugate Sales Market Share by Application (2021-2032)
  9. 5.3 Global Peptide Drug Conjugate Revenue by Application
  10. 5.3.1 Global Peptide Drug Conjugate Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Peptide Drug Conjugate Revenue by Application (2021-2032)
  12. 5.3.3 Global Peptide Drug Conjugate Revenue Market Share by Application (2021-2032)
6 Global Peptide Drug Conjugate Sales by Region
  1. 6.1 Global Peptide Drug Conjugate Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide Drug Conjugate Sales by Region (2021-2032)
  3. 6.2.1 Global Peptide Drug Conjugate Sales by Region (2021-2026)
  4. 6.2.2 Global Peptide Drug Conjugate Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Peptide Drug Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Peptide Drug Conjugate Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Peptide Drug Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Peptide Drug Conjugate Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Peptide Drug Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Peptide Drug Conjugate Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Peptide Drug Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Peptide Drug Conjugate Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Peptide Drug Conjugate Revenue by Region
  1. 7.1 Global Peptide Drug Conjugate Revenue by Region
  2. 7.1.1 Global Peptide Drug Conjugate Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Peptide Drug Conjugate Revenue by Region (2021-2026)
  4. 7.1.3 Global Peptide Drug Conjugate Revenue by Region (2027-2032)
  5. 7.1.4 Global Peptide Drug Conjugate Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Peptide Drug Conjugate Revenue (2021-2032)
  8. 7.2.2 North America Peptide Drug Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Peptide Drug Conjugate Revenue (2021-2032)
  11. 7.3.2 Europe Peptide Drug Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Peptide Drug Conjugate Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Peptide Drug Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Peptide Drug Conjugate Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Peptide Drug Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhongshan Laibo Ruichen Biopharmaceutical
  2. 8.1.1 Zhongshan Laibo Ruichen Biopharmaceutical Company Information
  3. 8.1.2 Zhongshan Laibo Ruichen Biopharmaceutical Business Overview
  4. 8.1.3 Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Product Portfolio
  6. 8.1.5 Zhongshan Laibo Ruichen Biopharmaceutical Recent Developments
  7. 8.2 XINOGEN (HONG KONG) PHARMA
  8. 8.2.1 XINOGEN (HONG KONG) PHARMA Company Information
  9. 8.2.2 XINOGEN (HONG KONG) PHARMA Business Overview
  10. 8.2.3 XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Product Portfolio
  12. 8.2.5 XINOGEN (HONG KONG) PHARMA Recent Developments
  13. 8.3 Tianjin Conjustar Biotechnology
  14. 8.3.1 Tianjin Conjustar Biotechnology Company Information
  15. 8.3.2 Tianjin Conjustar Biotechnology Business Overview
  16. 8.3.3 Tianjin Conjustar Biotechnology Peptide Drug Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Tianjin Conjustar Biotechnology Peptide Drug Conjugate Product Portfolio
  18. 8.3.5 Tianjin Conjustar Biotechnology Recent Developments
  19. 8.4 Lumosa Therapeutics
  20. 8.4.1 Lumosa Therapeutics Company Information
  21. 8.4.2 Lumosa Therapeutics Business Overview
  22. 8.4.3 Lumosa Therapeutics Peptide Drug Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lumosa Therapeutics Peptide Drug Conjugate Product Portfolio
  24. 8.4.5 Lumosa Therapeutics Recent Developments
  25. 8.5 Shanghai Pharmaceuticals
  26. 8.5.1 Shanghai Pharmaceuticals Company Information
  27. 8.5.2 Shanghai Pharmaceuticals Business Overview
  28. 8.5.3 Shanghai Pharmaceuticals Peptide Drug Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Shanghai Pharmaceuticals Peptide Drug Conjugate Product Portfolio
  30. 8.5.5 Shanghai Pharmaceuticals Recent Developments
  31. 8.6 Shanghai Huiyong Pharmaceutical
  32. 8.6.1 Shanghai Huiyong Pharmaceutical Company Information
  33. 8.6.2 Shanghai Huiyong Pharmaceutical Business Overview
  34. 8.6.3 Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Product Portfolio
  36. 8.6.5 Shanghai Huiyong Pharmaceutical Recent Developments
  37. 8.7 Gaorui Yaoye(Beijing)Technologies
  38. 8.7.1 Gaorui Yaoye(Beijing)Technologies Company Information
  39. 8.7.2 Gaorui Yaoye(Beijing)Technologies Business Overview
  40. 8.7.3 Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Product Portfolio
  42. 8.7.5 Gaorui Yaoye(Beijing)Technologies Recent Developments
  43. 8.8 BrightGene Bio-Medical Technology
  44. 8.8.1 BrightGene Bio-Medical Technology Company Information
  45. 8.8.2 BrightGene Bio-Medical Technology Business Overview
  46. 8.8.3 BrightGene Bio-Medical Technology Peptide Drug Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 BrightGene Bio-Medical Technology Peptide Drug Conjugate Product Portfolio
  48. 8.8.5 BrightGene Bio-Medical Technology Recent Developments
  49. 8.9 Beijing Shenogen Pharma Group
  50. 8.9.1 Beijing Shenogen Pharma Group Company Information
  51. 8.9.2 Beijing Shenogen Pharma Group Business Overview
  52. 8.9.3 Beijing Shenogen Pharma Group Peptide Drug Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Beijing Shenogen Pharma Group Peptide Drug Conjugate Product Portfolio
  54. 8.9.5 Beijing Shenogen Pharma Group Recent Developments
  55. 8.10 Theratechnologies
  56. 8.10.1 Theratechnologies Company Information
  57. 8.10.2 Theratechnologies Business Overview
  58. 8.10.3 Theratechnologies Peptide Drug Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Theratechnologies Peptide Drug Conjugate Product Portfolio
  60. 8.10.5 Theratechnologies Recent Developments
  61. 8.11 Cybrexa Therapeutics
  62. 8.11.1 Cybrexa Therapeutics Company Information
  63. 8.11.2 Cybrexa Therapeutics Business Overview
  64. 8.11.3 Cybrexa Therapeutics Peptide Drug Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Cybrexa Therapeutics Peptide Drug Conjugate Product Portfolio
  66. 8.11.5 Cybrexa Therapeutics Recent Developments
  67. 8.12 Bicycle Therapeutics
  68. 8.12.1 Bicycle Therapeutics Company Information
  69. 8.12.2 Bicycle Therapeutics Business Overview
  70. 8.12.3 Bicycle Therapeutics Peptide Drug Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bicycle Therapeutics Peptide Drug Conjugate Product Portfolio
  72. 8.12.5 Bicycle Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peptide Drug Conjugate Value Chain Analysis
  2. 9.1.1 Peptide Drug Conjugate Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peptide Drug Conjugate Production Mode & Process
  6. 9.2 Peptide Drug Conjugate Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peptide Drug Conjugate Distributors
  9. 9.2.3 Peptide Drug Conjugate Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst